This content is not available in your region. 


Por favor, tenga en cuenta que esta sección de la página web sólo está disponible en inglés

EU approves Chr. Hansen’s unique triple strain probiotic for poultry

GALLIPRO® Fit probiotic ready for EU market after approval from European Commission

Jan 18. 2021 15:34 GTM

Following a previous positive opinion from EFSA (European Food Safety Agency), GALLIPRO® Fit probiotic has now been approved for sale in the EU by the European Commission. GALLIPRO® Fit was first successfully launched in the US in 2017, followed by Australia in 2018 and the South African and Asian markets in 2019.

“We are really excited to get this approval after research data and field trials have documented the efficacy and safety of GALLIPRO® Fit. We see it as an official blue stamp of our probiotic solution for some of the poultry industry’s biggest challenges that customers in other parts of the world have benefitted from since 2017,” says Dorthe Sandvang, DVM, PhD, from Chr. Hansen’s Animal Health Innovation.

“GALLIPRO® Fit is the trademark for Chr. Hansen’s first probiotic to combine three unique strains in one product to address some of the key challenges faced by poultry producers today. Together, the three novel strains in GALLIPRO® Fit have been proven to effectively support the digestive performance and a healthy normal immune system in broilers, pullet layers/breeders and turkeys. At the same time, it brings production profitability,” she elaborates.

 

Success around the world 

With the registration and regulatory approval secured in Europe, Chr. Hansen is now able to bring the successful product to a new region – and is also preparing for a launch in a new EMEA markets in 2021.

“Over the past years we have witnessed a very positive adoption of GALLIPRO® Fit by customers in the US, Australia, Asia and South Africa. We can’t wait to bring this highly relevant solution to European and other EMEA markets,” says Christophe Bostvironnois, senior global product manager for Poultry at Chr. Hansen.

GALLIPRO® Fit has been proven to be effective in the following key areas:

  • Boosts husbandry management by supporting normal physiological functions
  • Contributes to food safety
  • Risk reduction of failure with specific laboratory assays

With feed representing 68% of the cost of broiler production1, production profitability is important, and margins are under pressure. 

Protecting poultry from Clostridium perfringens, Salmonella and Escherichia coli is key for farmers to get the highest productivity for their chickens. In 2019, 1 in 3 outbreaks of foodborne disease was due to Salmonella.  Poland, Spain and Slovakia reported the highest rate of Salmonella outbreaks that year.2 Also, uncontrolled clostridiosis in production systems can cost more than 0.05 €/ bird.3

GALLIPRO® Fit contains unique strains of bacteria that are selected for their relative effectiveness at demonstrating beneficial modes of action, making them particularly suitable for improving the success of commercial poultry operations.

“From our library of bacterial strains, we carefully select strains with a research-proven ability to influence animal welfare, support a normal immune system and keep birds healthier. With GALLIPRO® Fit we are bringing a tried and tested solution to help European poultry farmers protect their business,” concludes Bostvironnois.

 

 

References
1 Wageningen UR 2014
2 Wattagnet
3 Poultry world 2018 



GALLIPRO® Fit is a trademark of Chr. Hansen A/S

 

Chr. Hansen es una empresa global y diferenciada de biociencia que desarrolla soluciones con ingredientes naturales para las industrias de alimentación y nutrición, farmacéutica y agrícola. En Chr. Hansen, nos encontramos en una posición privilegiada para impulsar el cambio positivo mediante soluciones microbianas. Desde hace más de 145 años, trabajamos para facilitar la agricultura sostenible, las etiquetas más limpias y una vida más sana para más personas de todo el mundo. Nuestras plataformas de tecnología microbiana y fermentativa, incluida nuestra amplia colección de unas 40.000 cepas microbianas, tienen potencial para marcar un antes y un después. Al satisfacer las necesidades de los clientes y las tendencias internacionales, seguimos revelando el poder de las bacterias beneficiosas para responder a dificultades globales, como el desperdicio de alimentos, la salud en el mundo y el uso excesivo de antibióticos y plaguicidas. Como empresa de biotecnología más sostenible del mundo, llegamos a más de mil millones de personas cada día. Con el respaldo de nuestro legado de innovación y curiosidad para impulsar la ciencia, nuestro propósito de cultivar un mundo mejor naturalmente, «Grow a better world. Naturally» está en la esencia de todo lo que hacemos.


Compartir